SMT19969 as a treatment for Clostridium difficile infection: An assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 1, 2015, Pages 182-189

  Baines, S D ^a   Crowther, G S ^b   Freeman, J ^c   Todhunter, S ^b   Vickers, R ^d   Wilcox, M H ^b,c  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

^d SUMMIT PLC   (United Kingdom)

Author keywords

Antibiotics; Clostridium difficile; Cytotoxin; Gut model; Microflora; NAP1 027

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; CYTOTOXIN; METRONIDAZOLE; SMT 19969; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL SPORE; BACTERIUM ISOLATE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; IN VITRO STUDY; INTESTINE FLORA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPORE GERMINATION; STEADY STATE; BIOLOGICAL MODEL; DRUG EFFECTS; GASTROINTESTINAL TRACT; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; GASTROINTESTINAL TRACT; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL;

EID: 84928315839     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku324     Document Type: Article

References (32)

1. Bartlett J, Moon N, Chang TW et al. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Garstroenterology 1978; 75: 778-82.
2. George WL, Rolfe RD, Harding GK et al. Clostridium difficile and cytotoxin in feces of patients with antimicrobial agent-associated pseudomembranous colitis. Infection 1982; 10: 205-8.
3. Owens RC, Donskey CJ, Gaynes RP et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46: S19-31.
4. Kyne L, Hamel MB, Polavaram R et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34: 346-53.
5. O'Brien JA, Lahue BJ, Caro JJ et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007; 28: 1219-27.
6. Debast SB, Bauer MP, Kuijper EJ et al. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20 Suppl 2: S1-S26.
7. Nelson RL, Kelsey P, Leeman H et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2011; 7: CD004610.
8. Al-Nassir WN, Sethi AK, Nerandzic MM et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47: 56-62.
9. Bouza E, Dryden M, Mohammed R et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea. In: Abstracts of the Eighteenth European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, 2008. Abstract O464, p. S103, Blackwell, Hoboken, NJ, USA.
10. Pepin J, Alary ME, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 1591-7.
11. Goldstein EJ, Babakhani F, Citron D. Antimicrobial activities of fidaxomicin. Clin Infect Dis 2012; 55 Suppl 2: S143-8.
12. Chilton CH, Crowther GS, Freeman J et al. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line after vancomycin or metronidazole failure. J Antimicrob Chemother 2014; 69: 451-62.
13. Brazier JS, Fawley W, Freeman J et al. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 2001; 48: 741-2.
14. Baines SD, O'Connor R, Freeman J et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62: 1046-52.
15. Best EL, Freeman J, Wilcox MH. Models for the study of Clostridium difficile infection. Gut Microbes 2012; 3: 145-67.
16. Macfarlane GT, Macfarlane S, Gibson GR. Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microb Ecol 1998; 35: 180-7.
17. Brown RB, Martyak SN, Barza M et al. Penetration of clindamycin phosphate into the abnormal human biliary tract. Ann Intern Med 1976; 84: 168-70.
18. Freeman J, Baines SD, Saxton K et al. Effect of metronidazole on growth and cytotoxin production by epidemic Clostridiumdifficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 2007; 60: 83-91.
19. Miller M, Bernard L, Thompson M et al. Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridiumdifficile infection. Infect Control Hosp Epidemiol 2010; 31: 710-5.
20. Johnson S, Sanchez JL, Gerding DN. Metronidazole resistance in Clostridium difficile. Clin Infect Dis 2000; 31: 625-6.
21. Vickers R, Tinsley J, Wilson F et al. SMT19969: In vitro and in vivo evaluation of a novel antibiotic for Clostridium difficile infection. In: Abstracts of the Twenty-third European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 2013. Abstract P1655, Blackwell, Hoboken, NJ, USA.
22. Goldstein EJ, Citron DM, Tyrrell KL et al. Comparative in vitro activities SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 Gram-positive and Gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrob Agents Chemother 2013; 57: 4872-6.
23. Goldstein EJ, Citron DM, Tyrrell KL et al. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from35 less frequently recovered intestinal Clostridium species: implications for Clostridium difficile recurrence. Antimicrob Agents Chemother 2014; 58: 1187-91.
24. Baines SD, Freeman J, Wilcox MH. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother 2009; 53: 2202-4.
25. Baines SD, Freeman J, Wilcox MH. Effects of piperacillin/tazobactam on Clostridium difficile growth and cytotoxin production in a human gut model. J Antimicrob Chemother 2005; 55: 974-82.
26. Baines SD, Saxton K, Freeman J et al. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2006; 58: 1062-5.
27. Baines SD, O'Connor R, Huscroft G et al. Mecillinam: a low risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model. J Antimicrob Chemother 2009; 63: 838-9.
28. Corbett D, Wise A, Payne LJ et al. SMT19969: In vitro pharmacodynamics against Clostridium difficile. In: Abstracts of the Twenty-third European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 2013. Abstract P1654, Blackwell, Hoboken, NJ, USA.
29. Baines SD, O'Connor R, Saxton K et al. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2009; 63: 520-5.
30. Baines SD, O'Connor R, Saxton K et al. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 2008; 62: 1078-85.
31. Best E, Vickers R, Wilcox MH. Effects of a novel antimicrobial (SMT19969) for treatment of Clostridium difficile infection (CDI) on gut flora. In: Abstracts of the Fifty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, Colorado, 2013. Abstract K-167, ASM Press, Washington DC, USA.
32. Crowther GS, Chilton CH, Todhunter SL et al. Development and validation of a chemostat gut model to study both planktonic and biofilm modes of growth of Clostridium difficile and human microbiota. PLoS One 2014; 9: e88396.